Alligator Bioscience, a clinical-stage biotechnology company developing tumor-directed tumor immune antibody drugs, today provided a brief update on mitazarimab.
In parallel with ongoing collaboration activities, Alligator is exploring alternative opportunities for the Phase 3 development of mitazarimab in first-line metastatic pancreatic cancer. As part of these efforts, Alligator has signed a letter of intent with Unicancer, a French non-profit clinical cancer research organization. As a result, both parties are working together to establish the feasibility and prepare for a Phase 3 trial sponsored by global researchers.
No development decisions have been made at this time and such activities are still in the exploratory stage.
Visited 8 times, 1 visit(s) today
